HBV Capsid Disassembly via Premature Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus (HBV) infection are limited by drug resistance, low efficacy, and tolerability issues, and do not provide a cure, with chronic infections leading to liver diseases and hepatocellular carcinoma, highlighting the need for novel therapeutic agents that can effectively inhibit HBV replication and prevent disease progression.
Innovation Solution
Development of novel antiviral compounds, specifically those of Formula (I) X-A1-Y-A2-Z-L-R, which inhibit HBV proteins and interfere with the HBV life cycle by disrupting capsid assembly and disassembly, thereby reducing viral load and potentially eradicating the virus from the host.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (interferon and nucleoside analogues) are used to suppress HBV replication, then viral load is reduced, but drug resistance develops and efficacy is limited
Solution Approach 1:
The patent extracts the viral DNA from the capsid structure through compounds that induce premature disassembly, separating the viral genome from the protective capsid before it can establish persistent infection. This extraction approach targets a different stage of the viral life cycle compared to traditional polymerase inhibitors, thereby avoiding resistance mechanisms that have developed against existing therapies.
Solution Approach 2:
The compounds act as intermediary agents that bind to capsid proteins and induce conformational changes, serving as a mediator between the host cell and the viral particle. This intermediary mechanism disrupts the capsid assembly/disassembly equilibrium without directly targeting the viral polymerase, creating a novel therapeutic pathway that bypasses existing drug resistance.
2Reliability
If current therapies are administered chronically to suppress HBV, then disease progression is slowed, but treatment duration is prolonged and tolerability issues arise
Solution Approach 1:
The compounds perform preliminary action by disrupting capsid assembly early in the viral replication cycle, preventing the formation of stable cccDNA reservoirs in the nucleus. By acting preemptively on capsid maturation rather than suppressing established infection, the treatment may achieve viral clearance in a finite duration without requiring indefinite chronic therapy.
Solution Approach 2:
The invention changes the therapeutic parameter from suppressing viral replication (continuous chronic approach) to disrupting capsid stability (finite intervention approach). This parameter change transforms the treatment paradigm from long-term suppression to potentially curative disassembly, reducing overall treatment duration and associated tolerability issues.
3Reliability
If capsid assembly is disrupted to inhibit viral replication, then viral load is reduced, but abnormal capsid formation may occur
Solution Approach 1:
The compounds exert localized effects on specific regions of the capsid structure, inducing disassembly at targeted sites while preserving overall capsid integrity during normal assembly. This local quality approach allows selective disruption of pathological capsid states without globally affecting all capsid formations, thereby maintaining normal viral function while inhibiting replication.
Solution Approach 2:
The treatment dynamically modulates capsid assembly and disassembly equilibria rather than statically preventing assembly. By inducing reversible conformational changes that favor disassembly under viral replication conditions, the compounds adaptively control capsid morphology, allowing normal structure during assembly while promoting disassembly during replication, thus preventing abnormal permanent formations.
Data Source
AI summary
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:X-A1-Y-A2-Z-L-R  (I)which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.